ArticleFrontiers in medicine2026
Yiguanjian alleviates ocular surface inflammation and lacrimal gland immune dysregulation in experimental dry eye disease: evidence from
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent ocular surface inflammation and lacrimal gland immune dysregulation are central to the progression of dry eye disease (DED). Th17/Treg imbalance contributes to sustained inflammatory activation in the ocular surface and lacrimal gland. Yiguanjian (YGJ) has anti-inflammatory and immunomodulatory potential, but whether it can alleviate ocular surface inflammation and restore lacrimal gland immune homeostasis in DED remains unclear. Methods: A benzalkonium chloride (BAC)-induced rat DED model was used to assess the effects of YGJ on tear secretion, tear film break-up time, corneal fluorescein staining, ocular histopathology, lacrimal gland Th17/Treg proportions, related gene expression, and STAT3 signaling. Yiguanjian-containing serum (YCS) was prepared, and its serum-associated chemical features were characterized by UHPLC-Q-Orbitrap HRMS. A hyperosmotic non-contact co-culture system of rat lacrimal gland epithelial cells and activated CD4⁺ T cells was established to evaluate epithelial cell viability, intracellular reactive oxygen species (ROS), Th17/Treg differentiation, Foxp3 and IL-17A immunofluorescence signals, and related gene expression. AS2863619 and Peptide P60 were used to explore Foxp3-associated regulation. Results: In BAC-induced dry eye rats, YGJ improved tear secretion and tear film stability, reduced corneal fluorescein staining, and alleviated corneal and lacrimal gland histopathological injury, with partial preservation of meibomian gland and conjunctival morphology. YGJ reduced lacrimal gland Th17 proportions, restored Treg proportions, increased Foxp3 and IL-10 expression, decreased RORγt and IL-17A expression, and reduced lacrimal gland STAT3 phosphorylation. UHPLC-Q-Orbitrap HRMS yielded 67 candidate annotations corresponding to 56 distinct LC-MS features in YCS. In the hyperosmotic co-culture model, YCS improved epithelial cell viability, reduced ROS accumulation in CD4⁺ T cells, suppressed Th17-related responses, and enhanced Treg-associated immunoregulation. AS2863619 produced effects comparable to YCS, whereas Peptide P60 weakened Foxp3-associated immunoregulation; combined YCS treatment partially attenuated Peptide P60-induced changes. Conclusion: YGJ attenuated DED-related inflammatory injury
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.